Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
bevacizumab + olaparib + durvalumab
- Development stage
- Phase 2
- Lead developer
- AstraZeneca
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous, Oral
01
Overview
A triple combination therapy consisting of bevacizumab (an anti-VEGF monoclonal antibody), olaparib (a PARP inhibitor), and durvalumab (an anti-PD-L1 monoclonal antibody). This combination targets multiple pathways in cancer treatment: inhibiting angiogenesis, preventing DNA repair in cancer cells, and enhancing immune response against cancer cells. The synergistic effect is particularly notable in ovarian cancer treatment, where bevacizumab creates a hypoxic environment that may increase sensitivity to PARP inhibition by olaparib, while durvalumab counteracts immunosuppression in the tumor microenvironment.
- Brand names
- Imfinzi + Avastin + Lynparza
- Other names
- durvalumab + bevacizumab + olaparib
02
Targets
PARP1 (Poly (adp-ribose) polymerase 1)PARP2 (Poly (adp-ribose) polymerase 2)CD274 (Programmed cell death protein 1 ligand 1)VEGFA (Vascular endothelial growth factor A)
Beyond the preview
Go deeper on bevacizumab + olaparib + durvalumab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on bevacizumab + olaparib + durvalumab.